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ABSTRACT
Paraproteinemia is precipitated by an accumulation of monoclonal plasma cells or B lymphocytes. Idiopathic
neuropathies that are associated with paraproteinemia account for only 10% of the neuropathies. Paraprotein acts like
an antibody and is targeted against myelin and axons present in the peripheral nerves. Despite being of interest for
quite a long time, the caudal relationship between paraproteinemias and peripheral neuropathies still remains a
sorcery. We report a case of a middle aged male who presented with pain and parasthesias in both arms and legs. His
workup revealed him to be having a paraproteinemic neuropathy consistent with IgA Lambda chains that account for
being the most rare type of monoclonal gammopathy than IgM or IgG having the potential to progress to smouldering
multiple myeloma.
KEY WORDS: Monoclonal gammopathy; Paraproteinemia; Peripheral neuropathy; Multiple myeloma

INTRODUCTION: Paraproteinemic neuropathies are a
heterogeneous group of neuropathies, which share the
common feature of a homogeneous immunoglobulin in
the serum. Approximately 10% of all idiopathic
neuropathies are associated with paraproteinemia.[1]
Monoclonal gammopathy of undetermined significance
(MGUS) occurs in over 5.3% of the general population
over the age of 70 and the incidence increases with
age being more common in men.[2] The type of M
protein in monoclonal gammopathy associated with
peripheral neuropathy is most commonly IgM while IgG
and IgA neuropathies are less common.[3] In one study,
approximately 60% of neuropathies associated with
monoclonal gammopathy were IgM, 30% were IgG, and
10% were IgA. [4] IgA protein appears to be associated
with a lesser predilection for causing peripheral
neuropathy compared to IgM or IgG MGUS
combined.[5] In a study of 74 patients with MGUS, 8 of
26 IgM MGUS patients (31%) had neuropathy,
compared to 2 of 34 IgG MGUS patients (6%) and 2 of
14 IgA MGUS patients (14%).[5] Paraproteinemic
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neuropathy IgA affects some or all sensory
modalitieswhich cause allodynia, hyperpathia, cramps
with distal weakness. These neuropathies are typically
manifested neurologically as a demyelinating type of
sensori-motor polyneuropathy. Sometimes, multi-organ
involvement is also seen. Patients with paraproteinemic
neuropathy have an increased risk of axial bone
fractures, thrombo embolism, peripheral neuropathy
and secondary malignancies.[6] Therapies for IgA
paraproteinemic neuropathy depend on the particular
subtype,the patho-physiology involved, ranging from
intravenous immunoglobulins (IVIGs), plasma exchange
sessions, corticosteroids, rituximab and various
chemotherapies. In terms of response to therapy there
is no distinction seen between demyelinating and
axonal patterns of neuropathy,Possible malignant
conversion of underlying benign monoclonal
gammopathy has to be closely monitored with risk
factors for malignant transformation including
progressive worsening of neuropathy and rising titers of
monoclonal protein.[7]
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Case Report:

criteria for MGUS established by the International
Myeloma Working Group and the World Health
organization consistent with IgA lambda monoclonal
gammopathy, Therefore, the final diagnosis of IgA
paraproteinemic neuropathy associated with MGUS
was made. The patient was given a trial of 5 sessions of
plasmapheresis. Mild improvement in motor and
sensory symptoms was observed, however, his bilateral
foot
drop
persisted.
He
was
given
an
ankle-foot-orthosis (AFO) for his foot drop. He is
undergoing physiotherapy and has been advised regular
follow ups in Neurology and Oncology clinics to plan for
immunomodulatory treatment.

A 52 years of age Pakistani male presented to
neurology clinic with a 12 months history of numbness,
tingling, pain in both lower extremities and symptoms
progressed to involve both his arms for 6 months. Three
months prior to presentation he started developing
slowly progressive asymmetrical weakness of both legs,
without any sphincteric involvement. There was no
history of fever, cough, diarrhea or constipation. There
was no past history of joint pains, weight loss,
photosensitivity, polyuria or polydipsia. He belongs to a
poor socioeconomic group and is a gardener by
occupation with 3 children. He is a nonsmoker and
denies alcoholism. There is history of essential
hypertension for 3 years and he is on tablet atenolol
50mg daily. Rest of the drug and family history were nil
of note. On physical examination, a middle-aged
gentleman alert and oriented to time, place and
person. The patient's oral temperature was 98.6°F with
a regular pulse of 68 beats/minute. His blood pressure
was 130/80 mm Hg with no postural drop and
respiratory rate was 14/ minute. He had distal wasting
of lower extremities with bilateral footdrop (Figure, A).
Muscle tone was decreased in all four limbs with
areflexia and bilaterally mute plantar response. He had
a Medical Research Council (MRC) sum score of
30/60. Pin prick sensation was lost in a glove and
stocking distribution with normal perianal sensation. He
had a high steppage gait. Signs of meningeal irritation
were absent. Abdominal examination was did not reveal
any palpable mass, organomegaly or ascites. The
patient's precordial examination revealed normal heart
sounds and chest examination revealed normal
vesicular
breathing.
The
laboratory
analysis
demonstrated a normal blood complete picutre and
erythrocyte sedimentation rate. Liver and renal function
tests, serum glucose levels, muscle enzymes, ECG and
chest X-ray were unremarkable. His nerve conduction
studies and electromyography were consistent with a
chronic sensori-motor demyelinating type of
polyneuropathy with secondary axonal damage (Figure,
B). Lumbar puncture for CSF analysis showed elevated
CSF protein of 0.92g/l. His HbA1c, thyroid function
tests, and serum B12 levels were normal. His ANA, RA
factor, HIV serology, HbsAg, and anti-HCV were
negative. CT scan of the chest, abdomen, and pelvis
were unremarkable. Serum protein electrophoresis
revealed a discrete spike in the monoclonal paraprotein
consisting of IgA Lambda with serum IgA levels
markedly raised to 13 mg/dl (Normal range 1-7 mg/dL)
(Figure, C) Urine for Bence Jones proteins didn’t show
light chains. Bone scan, skeletal survey and bone
marrow biopsy were negative.Our patient fulfilled the
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Figure A: BILATERAL FOOT DROP

Figure B: Figure B: Nerve Conduction studies showing a
demyelinating pattern with a motor amplitude drop,
prolong latencies and an abnormal temporal dispersion

Figure C: Serum protein electrophoresis showing an IgA
spike (arrow head)
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DISCUSSION:

technique used to eliminate pathogenic antibodies but
its role has not been fully proven through trials.
Interferon alpha was also found to beneficial in one
trial.[13] These treatment regimens produce only a
transitory improvement and require recapitulation for
several months depending upon the patient’s
response. If one treatment modality is unsuccessful,
one may initiate an alternative modality which may lead
to alleviation of symptoms. More studies are required
to have a better understanding of the patho-physiology
of various mechanisms involved and better biomarkers
to ascertain the usefulness and efficacy of therapy.

Patients with paraproteinemic disorders exhibit distinct
neuropathic phenotypes, often with characteristic
identifiable clinical features. Frequently prognosis is not
well-defined and in many cases is still unknown.
Neuropathies can lead to disability, loss of
independence and social isolation especially in the
elderly. They warrant adequate work up for diagnosis
which may sometimes be very extensive. Neuropathies
associated with paraproteinemia have heterogeneous
clinical, neurophysiological, neuropathological and
hematological features. These necessitate prompt and
appropriate work up and management to avoid
permanent disability. There is no known role until now
for chemotherapy and no treatment is recommended
and required for patients with MGUS.[8] These patients
must be followed over time with history and clinical
assessment for disease progression. All patients should
undergo laboratory evaluation for disease progression
six months after diagnosis with serum and urinary
M-protein, complete blood count, creatinine, and
serum calcium. Periodic laboratory testing should then
be done in follow-up of high-risk patients using a risk
stratification system as not all persons with MGUS have
the same risk of disease progression. Therefore, the
management of a patient with MGUS requires an
understanding of the risk of progression to symptomatic
disease requiring therapy. MGUS neuropathy is closely
linked to chronic inflammatory demyelinating
polyneuropathy.[9] However, this association still
remains unclear. The paramount feature of CIDP i.e
conduction blocks sometimes occur in MGUS as well.
The cerebrospinal fluid (CSF) proteins are usually
elevated in both these conditions and their response to
immune-modulating treatments is substantial.[10]
The EFNS guidelines on the treatment options of
chronic
inflammatory
demyelinating
polyradiculoneuropathies also suggests screening for
paraproteins in all the patients diagnosed as CIDP and
if the screening comes out to be positive then it must
be labeled as paraproteinemia.[11] The appropriate
therapy for paraproteinemic neuropathies has yet to be
established. Patients with
IgA MGUS improve
symptomatically within days or weeks after high-dose
intravenous immunoglobulins (0.4 g/kg of body weight)
daily for 5 days, a total of 4 to 5 plasma exchange
sessions (a total of 220 ml/kg) or therapy with
corticosteroids
often
in
combination
with
immune-suppressants. Class I evidence documents
plasma exchange to be effective in peripheral
neuropathies associated with MGUS of the IgG and IgA,
but not IgM, types.[12] Another treatment is
immunoadsorption, which is a blood purification

PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES

REFERENCES
1.
2.
3.
4.

5.

6.

7.

49

Rison RA, Beydoun SR. Paraproteinemic
neuropathy: a practical review. BMC Neurol.
2016;16(1):13.
Kyle RA, Rajkumar SV. Monoclonal gammopathies
of undetermined significance. Hematol. Oncol.
Clin. North Am.1999;13(6):1181-202.
Ramchandren S,Lewis RA. An update on
monoclonal gammopathy and neuropathy. Cur
Neurol Neurosci Rep. 2012; 12(1):102-110.
Yeung KB, Thomas PK, King RH, et al. The clinical
spectrum of peripheral neuropathies associated
with benign monoclonal IgM, IgG and IgA
paraproteinemia.
Comparative
clinical,immunological and nerve biopsy findings. J
Neurol. 1991;238(7):383-391.
Nobile-Orazio E, Barbieri S, Baldini L, et al.
Peripheral neuropathy in monoclonal gammopathy
of undetermined significance: prevalence and
immunopathogenetic studies. Acta neurol Scand.
1992;85(6):383-390.
Wadhera RK, Rajkumar SV. Prevalence of
monoclonal gammopathy of undetermined
significance: a systematic review. Mayo Clin Proc.
2010;85(10):933-942.
Živković SA, Lacomis D, Lentzsch S.

VOL. 14 (2)

APRIL- JUNE 2019

Paraproteinemic neuropathy. Leuk. Lymphoma
2009;50(9):1422-33.
8. Terpos E, Morgan G, Dimopoulos MA, Drake MT,
Lentzsch S, Raje N, Sezer O, García-Sanz R, Shimizu
K, Turesson I, Reiman T. International Myeloma
Working Group recommendations for the treatment
of multiple myeloma–related bone disease. J Clin
Oncol. 2013;31(18):2347.
9. Gorson KC, Allam G, Ropper AH. Chronic
inflammatory demyelinating polyneuropathy Clinical
features and response to treatment in 67
consecutive patients with and without a monoclonal
gammopathy. Neurol. 1997;48(2):321-8.
10. Simmons Z. Paraproteinemia and neuropathy. Curr
Opin Neurol. 1999;12(5):589-95.

11. Hughes RA, Bouche P, Cornblath DR, Evers E,
Hadden RD, Hahn A, Illa I, Koski CL, Leger JM,
Nobile‐Orazio E, Pollard J. European Federation of
Neurological Societies/Peripheral Nerve Society
guideline on management of chronic inflammatory
demyelinating polyradiculoneuropathy: report of a
joint task force of the European Federation of
Neurological Societies and the Peripheral Nerve
Society. Eur J Neurol. 2006;13(4):326-32.
12. Wicklund MP, Kissel JT. Paraproteinemic
neuropathy.
Curr
Treat
Options
Neurol.
2001;3(2):147-56.
13. Lehmann HC, Hartung HP. Plasma exchange and
intravenous immunoglobulins: mechanism of
action in immune-mediated neuropathies.J
Neuroimmunol.2011;231(1-2):61-9.

Conflict of interest: Author declares no conflict of interest.
Funding disclosure: Nil
Author’s contribution:
Waleed Shahzad; concept, data collection, data analysis, manuscript writing, manuscript review
Sumaira Nabi; data collection, data analysis, manuscript writing, manuscript review
Hafiza faiza Mushtaq; concept, data collection, data analysis, manuscript writing, manuscript review
Tehmina Inayat; data collection, data analysis, manuscript writing, manuscript review
Muhammad Hassan; data collection, data analysis, manuscript writing, manuscript review
Haris Majid Rajput; data collection, data analysis, manuscript writing, manuscript review

PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES

50

VOL. 14 (2)

APRIL- JUNE 2019

